All Episodes
CME — 418 episodes · page 2 of 5
First 5 Minutes®: Empowering Shared Decisions in Lung Cancer Screening
Setting the Stage: Why Rethinking IBD Care Matters Now
Defining Success in IBD: Treat-to-Target
Where Conventional IBD Therapies Fall Short
Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment
Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations
Gut-Selective Therapy: Understanding Anti-Integrins in IBD
Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
The Cortisol Clue: Diagnosing Hypercortisolism in People with Difficult-to-Control Cardiometabolic Conditions
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
The IL-36 Connection: Immunology’s Role in GPP Pathogenesis and Therapy
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Survey Says: Aligning Early Advanced IBD Therapy with Patient Priorities
Diabetes Educators EmpowerED: Strategies for Optimizing Patient Outcomes With Emerging Weekly Insulin Therapies
Breaking the Code: Mechanisms and Future Therapies for Refractory Chronic Cough
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
IBD in Focus: A Case-Based Approach to Diagnosis and Assessment
Movements With Meaning: Reading the Pattern, Not the Label
Counseling Patients on Their Future with Biologics
When Movements Steal Lives: TD Burden, Stigma, and the Therapeutic Alliance
Subtle vs Syndromic: Distinguishing TD from Other DIMDs in the Neuro Clinic
The 15-Minute Med Check: Making AIMS and TD Screening Routine in Psychiatry
Closing the Gap: Equity, Disparities, and Access to TD Diagnosis and Care
Not All VMAT2s Are the Same: Understanding the PK/PD Differences
From “EPS” to Personalized TD Treatment: Matching VMAT2 MOA to the Patient
Treating the Complex Patient: TD Management in Older Adults and Medically Fragile Populations
Shared Decisions, Real Patients: Patient-Centered TD and Antipsychotic Strategies
From Evidence to Everyday Practice: Using Real-World Data to Refine TD Algorithms
VMAT2 in the Real World: Recently Presented PRO Data That Should Change TD Practice
CGM in the Real T2D World
Sjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
FXIa Remix! Keeping the Flow Without Missing a Beat
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Case Challenges in Systemic Mastocytosis: Clinical Insights From the Expert Roundtable
Diagnostic Challenges in Refractory Chronic Cough: From Burden to Solutions
Brain Metastases Management: From Detection to Multidisciplinary Care
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
Managing Brain Metastases Through Multidisciplinary Team Collaboration
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
DKA in the Real World: Evidence and Cases that Matter
IBD Beyond Symptoms: What Community GIs Need to Know
Pathophysiology of IBD: The War Within
Targeting Inflammation in IBD: Localized vs Systemic Strategies
Beyond Biology: Environmental and Lifestyle Influences in IBD
Understanding the Microbiome’s Role in IBD Management
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Putting It All Together: Challenges Addressed
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
A Seat at the HS Expert’s Table: A Master Class in Diagnosis and Treatment Advances for Hidradenitis Suppurativa
Leveraging CGM to Its Full Potential in People with T2D
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
Target Locked in gMG: Why T2T Matters
Minimal By Design: Define MSE Endpoints
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
The IgG Clock: Redose Using IgG Kinetics
Escalate With Intention: Stepwise, Target-Anchored Moves
Shared Goals, Shared Gains: Align With Patient Preferences
The 2-Point Signal: Apply ≥2-Point Rule
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Hepatic Encephalopathy: An Ominous Sign
The Clinical Spectrum of Hepatic Encephalopathy
Hepatic Encephalopathy: Tipping the Balance
You Can’t Diagnose MHE Unless You Diagnose Cirrhosis
Diagnosing Minimal Hepatic Encephalopathy: There's an App for That?
Hepatic Encephalopathy: What's Sarcopenia Got to Do With It?
Treatment of Overt Hepatic Encephalopathy
Hepatic Encephalopathy: Unmet Therapeutic Needs
Advances in the Treatment of Hepatic Encephalopathy
Treatment Revolution in IgA Nephropathy
The CONFIDENCE Trial: Data Insights
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
First Results From Cohort 4 of the SunRISe-1 Trial
Trial in Progress: Phase 3 MoonRISe-3 Study
Consequences of COVID-19: Addressing Infection-Associated Chronic Conditions
Cardio-Oncology: Key Clinical Data from ACC.23
The New POSEIDON Criteria: The WHY, the WHAT, and the HOW
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer